Improving communication between patients and doctors in ovarian cancer care
Official title: Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care
Funded at Dana-Farber Cancer Inst · NIH-11077348 · Data updated 2026-11-12
This study is working to help people with advanced ovarian cancer have better conversations with their doctors, using new technology to make communication easier and improve their overall well-being.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 15, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $133,300 |
| NIH project number | 5K23NR020219-03 |
| Project ID | NIH-11077348 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced ovarian cancer who are seeking to improve their communication with healthcare providers.
✕Less likely to help
Patients with early-stage ovarian cancer or those not receiving treatment may not benefit from this research.
What this research studies
This research aims to enhance patient-centered communication (PCC) for individuals with advanced ovarian cancer, who often face significant physical and psychological challenges. The project will develop and pilot test a new intervention that encourages patients and their healthcare providers to engage in more effective communication during clinical visits. By utilizing advanced technology like natural language processing, the study seeks to objectively assess communication behaviors, making it easier to identify areas for improvement. The ultimate goal is to improve the overall health-related quality of life for patients through better communication.
Why it matters
Potential benefit: If successful, this research could lead to improved health outcomes and quality of life for patients with ovarian cancer by fostering better communication with their healthcare providers.
How similar studies have gone: While there have been successful interventions aimed at improving communication in cancer care, this specific approach using natural language processing is relatively novel.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Pozzar, Rachel — Dana-Farber Cancer Inst
- Study coordinator: Pozzar, Rachel
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.